Calliditas Therapeutics
Latest round
- Series C
Last raised
- Oct 2013
Total raised
- $20M
Investors
- 2
About Calliditas Therapeutics
Calliditas Therapeutics AB specializes in biopharmaceuticals, specifically targeting rare diseases. The company was founded in 2004 and is headquartered in Stockholm, Sweden. Over its history, it has completed a total of 8 deals, with its most recent deal occurring on June 15, 2018.Calliditas Therapeutics AB focuses on developing and marketing innovative therapeutics for rare diseases, primarily targeting renal and hepatic conditions. Their flagship products include TARPEYO® (budesonide) delayed release capsules and Kinpeygo®, both designed to address IgA nephropathy and other orphan indications. TARPEYO® aims to reduce proteinuria in patients suffering from this progressive kidney disease, while Kinpeygo® serves as an adjunct in the treatment of various hepatic disorders.Calliditas Therapeutics generates revenue through the sale of its proprietary medications, specifically TARPEYO® and Kinpeygo®.57 mn.000 mn, to support upcoming product launches and expand into new geographic markets. The company aims to develop additional therapeutics for renal diseases and anticipates releasing new products in the coming years. Specifically, Calliditas is targeting expansion into further markets in Europe and North America by 2025, enhancing its market presence and accessibility of its innovative treatments.
Who invested in Calliditas Therapeutics
2 investors across 2 rounds
See all investors in Calliditas Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Calliditas Therapeutics
Who invested in Calliditas Therapeutics?
Calliditas Therapeutics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Calliditas Therapeutics raised?
Calliditas Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Calliditas Therapeutics last raise money?
Calliditas Therapeutics's most recent round on record is a Series C, in Oct 2013.
What does Calliditas Therapeutics do?
Calliditas Therapeutics AB specializes in biopharmaceuticals, specifically targeting rare diseases.
Where is Calliditas Therapeutics headquartered?
Calliditas Therapeutics is headquartered in Stockholm, Sweden.
Which VCs invest in companies like Calliditas Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at Calliditas Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Calliditas Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.